Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XYA 02

Next Previous
Drug Profile

XYA 02

Alternative Names: XYA-02

Latest Information Update: 16 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XYone Therapeutics
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 16 Jul 2026 Xyone Therapeutics has patents pending for XYA 02 in USA
  • 26 Jun 2026 XYone Therapeutics plans a phase Ib/II trial for Solid tumors (Late stage disease, Second line therapy or greater, Metastatic disease, Inoperable/Unresectable) in Australia (IV, infusion) (NCT07670312)
  • 17 Apr 2026 Preclinical trials in Non-small cell lung cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top